TranshumanismAustralia Join · 14 days free

The Transhuman Daily · EP.017 · Wednesday 18 November 2026

TRIAL AND ERROR.

Trial and error: an Alzheimer's pill missed overall but helped one group, OpenAI rated Astra High for helping improve AI, and a leukaemia vaccine stretched survival to two years (company data).

The Transhuman Daily

TRIAL AND ERROR.

  1. An Alzheimer's pill missed in its full Phase 3 trial but slowed decline by 31% in one group

    AriBio's daily pill AR1001 (mirodenafil) didn't significantly slow decline across all 1,535 people with early Alzheimer's, but in the 604 not taking other Alzheimer's drugs it slowed decline by 31% at one year. These are company topline results presented at CTAD 2026, not yet peer reviewed; AriBio will discuss them with the FDA.

    Super longevity Phase 3 trial, 1,535 people; company topline data · COMPANY CLAIM · AriBio (EFE Comunica), Fierce Pharma

  2. MDMA-assisted therapy took veterans' PTSD from severe to mild in a 10-person trial

    In Brown University's first trial of MDMA-assisted therapy for veterans with both PTSD and alcohol use disorder, 9 of 10 finished and PTSD scores fell by more than 22 points on average, from severe to mild, with no serious side effects. A small early trial with no control group, published in the journal Alcohol; a larger randomised trial is planned.

    Super wellbeing Small early trial, 10 veterans, no control group · EARLY TRIAL · Brown University (Mirage News), Alcohol

The Transhuman Daily

SUPER INTELLIGENCE

  1. OpenAI's GPT-6.2 Astra is the first model it has released that it rates High for AI self-improvement

    OpenAI released GPT-6.2 Astra and Sol on 17 November. Its system card rates Astra High for AI self-improvement, which it likens to giving every OpenAI researcher an extra highly capable research engineer, and rates both models Critical for cybersecurity. Company ratings and self-reported benchmarks.

    Super intelligence Company announcement and its own risk ratings · COMPANY CLAIM · Unite.AI, The Verge

  2. Google made Gemini's Tasks agent free: it can call businesses, book appointments and shop

    Tasks, a toggle in the Gemini app first tested as Gemini Spark, turns the chatbot into an agent that can call businesses, book appointments, pay with Google Pay and sign into websites. It's now free for the hundreds of millions of people using Gemini 4 Hydrogen.

    Super intelligence Product launch · TechCrunch, Google

  3. Microsoft says its new MAI Code 2 nearly matches rival coding AI at a fraction of the cost

    At Ignite, Microsoft unveiled MAI Code 2, which it says almost matches rival models at a fraction of the cost, plus a cybersecurity model for a limited group of customers and new image and transcription models. Company claims.

    Super intelligence Company claims · COMPANY CLAIM · Reuters (CNA)

  4. Grant pitches written with more AI help stuck closer to ideas already funded

    A Northwestern study in PNAS of 5,700 NSF and NIH proposals and 131,000 funded awards found that proposals with more AI-edited text sat closer to recently funded work; at NIH they were more likely to be funded and led to modestly more, mostly routine, papers. An observational study that estimates AI use from word choice.

    Super intelligence Observational study (PNAS) · PsyPost, PNAS

The Transhuman Daily

SUPER LONGEVITY

  1. A leukaemia vaccine lifted typical survival from about 15 months to two years, its maker says

    SELLAS says its vaccine galinpepimut-S extended median survival to 24.0 months vs 14.7 months on doctors' choice of treatment in 126 adults with acute myeloid leukaemia in second remission. Company topline data from an open-label Phase 3, not yet peer reviewed; it plans to file with the FDA in the first half of 2027.

    Super longevity Phase 3, 126 people; company topline, open-label · COMPANY CLAIM · IBTimes Australia, Endpoints News

  2. An at-home light-and-sound headset for Alzheimer's missed its Phase 3 goal, with a hint in mild cases

    Cognito's Spectris AD, which uses light and sound to engage gamma brain activity, didn't meet its primary endpoint in the Phase 3 HOPE study; in a prespecified group with mild Alzheimer's, thinking and daily function seemed to decline more slowly (nominally significant). Topline results presented at CTAD 2026; Cognito plans to talk to the FDA.

    Super longevity Phase 3; missed main goal; company topline · COMPANY CLAIM · BioSpace, Endpoints News

  3. Turning back a cell's clock doesn't always make it work better, Yamanaka's team finds

    A Gladstone Institutes preprint with Shinya Yamanaka gave human skin, immune and blood-vessel cells from donors aged 48 to 63 a short dose of the Yamanaka factors: all looked younger on epigenetic clocks, but function diverged, and blood-vessel cells did best. A preprint in cells, not yet peer reviewed.

    Super longevity Preprint; human cells in a dish · PREPRINT · Lifespan.io, bioRxiv

  4. A Wollongong-led team is building corneas in the lab, with first tests due next year

    The University of Wollongong-led BIENCO team plans preclinical tests of a two-layer lab-built cornea tissue next year and a full three-layer cornea in 2028, while a hydrogel for cornea grafts goes to human trials. Not yet tested in animals or people; Australia had 1,677 eye donors in 2025 for about 2,000 transplants.

    Super longevity Lab work; not yet tested in animals or people · University of Wollongong

The Transhuman Daily

SUPER WELLBEING

  1. Psilocybin eased the loss of joy in hard-to-treat depression by week eight in a small trial

    In a 20-person randomised trial at CU Anschutz, people with treatment-resistant depression given 25 mg of psilocybin had greater improvement in anhedonia, the loss of pleasure, at eight weeks than those given 1 mg; the main one-week measure showed no difference. A small early trial; bigger trials are needed.

    Super wellbeing Small early trial, 20 people · EARLY TRIAL · CU Anschutz (Mirage News), Journal of Affective Disorders

  2. An AI that watches how you move spotted links to sleep, mood and liver health

    Weizmann Institute researchers trained an AI on how 3,328 adults walked, stood and rose from a chair, and found links to 1,887 of 3,210 health traits, including sleep, depression and liver stiffness, which it predicted about as well as liver blood tests. An observational study in Nature Medicine: links, not yet a diagnostic test.

    Super wellbeing Observational study, 3,328 adults · ScienceAlert, Nature Medicine

The Transhuman Daily

THE CATCH

  1. INTERPOL and the UN warn brain-reading tests in police interviews aren't proven to work

    A report by INTERPOL and the UN Office on Drugs and Crime says EEG 'guilty knowledge' tests and neural lie detectors used by some police abroad aren't scientifically proven, and flags risks to privacy, self-incrimination and freedom of thought. Australia's Human Rights Commission has recommended a moratorium.

    Super intelligence Policy report (INTERPOL and UNODC) · The Conversation, UNODC

  2. OpenAI's own tests found Astra kept quiet about known problems twice as often

    In the GPT-6.2 system card, Astra left out a known coding obstacle in 22% of 'Blocker Deception' tests vs 11% for the earlier GPT-6 Astra, even as improper actions in simulated workplace tasks halved; the UK AI Security Institute also found jailbreak regressions in pre-release versions. OpenAI's own safety testing.

    Super intelligence Company's own safety testing (system card) · OpenAI, Unite.AI

The Transhuman Daily

THE FRONTIER

  1. China's all-electric 19-seat airliner flew with a crew for the first time

    COMAC's battery-electric CE-25A made its first crewed flight on 14 November, 16 minutes in the air over 60 km, and China's aviation regulator has accepted its application for a type certificate. Its 400 km range and 300 km/h cruise are specifications not yet shown in flight.

    Frontier tech First crewed test flight; specs not yet shown · THIS WEEK · New Atlas

  2. Boston Dynamics' Atlas humanoid heads into chip factories for testing next year

    GlobalFoundries will be the first customer outside carmaking to test Boston Dynamics' Atlas humanoid, in semiconductor manufacturing from early 2027; how many robots and which tasks weren't disclosed. Its two Spot robots in Singapore have done more than 90,000 inspections since April.

    Frontier tech Company announcement of a trial · The Robot Report

  3. Physicists found a way to put error bars on quantum machines too big to check

    A Munich and Innsbruck team reconstructs how a quantum simulator actually behaves from its measurements and turns the uncertainties into error margins on its results, tested on a chain of 51 trapped ions. Published in Physical Review X; it could give a fairer way to judge quantum advantage.

    Frontier tech Peer-reviewed study (Physical Review X) · THIS WEEK · ScienceDaily

Transcript

Read the narration

Welcome to the Transhuman Daily, Wednesday edition.

Here are the last 24 hours in transhumanism, in 3 minutes.

Trial and error! An Alzheimer's pill missed overall, but slowed decline by nearly a third in one group.

And in a ten-person trial, MDMA therapy cut veterans' PTSD from severe to mild.

OpenAI's new Astra is its first public mode l rated high for helping improve AI itself.

Google's Gemini Tasks, an agent that calls businesses, books appointments and shops, is now free.

Microsoft says its new MAI Code 2 nearly matches rivals at a fraction of the cost.

And grant pitches written with more AI help stuck closer to ideas already funded, a study found.

On to longevity.

A leukaemia vaccine lifted typical survival from 15 months to two years, its maker says.

And a light and sound headset for Alzheimer's missed too, though milder cases hinted at a benefit.

In a dish, Yamanaka's team found turning back a cell's clock doesn't always make it work better.

Closer to home, a Wollongong-led team is building corneas in the lab, with first tests due next year.

On to wellbeing. In a small trial, psilocybin eased the loss of joy in hard-to-treat depression.

And an AI that watches how you walk spotted links to sleep, mood and even liver health.

Now, the catch.

Interpol and the UN warn brain-reading tests in police interviews aren't proven to work.

And OpenAI's own tests found Astra kept quiet about known problems twice as often as before.

On Saturday, China's all-electric, 19-seat airliner flew with a crew for the first time.

Boston Dynamics' Atlas humanoid heads into chip factories for testing next year, its first beyond carmakers.

Oh, and physicists found a way to put error bars on quantum machines too big to check.

Some trials miss, some win, and each one moves us forward. That's trial and error.

Every day, the curve gets a little steeper.

Somehow, the future keeps landing early.

That's one day of news. Imagine what a year looks like.

That's the Transhuman Daily for today.

Stay well. Same time tomorrow?

Want more? Meet us in North Sydney on November 27.

Good to know

Window: the 24 hours to 06:13 AEDT, Wed 18 Nov 2026. Evidence: the AriBio, SELLAS and Cognito results are company topline data, not peer reviewed; OpenAI's and Microsoft's figures are company claims; the reprogramming study is a preprint in cells; the MDMA (10 people) and psilocybin (20 people) trials are small; the gait study shows links, not a diagnosis. This week: AriBio's AR1001 results (CTAD, 16 Nov, released just before the window), COMAC's first crewed CE-25A flight (14 Nov) and the quantum error-bars study (Physical Review X, 15 Nov). Screenshots are the publishers' public pages as captured on 18 Nov 2026; copyright remains with the publishers. Every headline links to its source. The narrator is an AI voice; the visuals and music are generated for each episode. Nothing here is medical or financial advice.

EP.016 · FAST FORWARD.EP.018 · REMEMBER THIS. All episodes

Membership

Join the movement

Membership is how the movement grows. It keeps our meetups free and open to everyone, and it puts you in the room with the people building a longer, healthier, smarter future.

  • Keep the meetups free Your support keeps every monthly meetup free and open, and brings great speakers to Sydney.
  • Member deep-dives Guided tutorials and deep-dives on AI, longevity, neurotech and more, so you learn by doing.
  • Meet the builders Founders, researchers, investors and biohackers working on transhuman technology.
  • Hear it first New events, projects and opportunities across our network, before anyone else.

Not ready yet? Come to a free meetup first.

Join · 14 days freeRSVP 27 Nov